Literature DB >> 11992301

Serologic immunity to diphtheria and tetanus in the United States.

Geraldine M McQuillan1, Deanna Kruszon-Moran, Adamadia Deforest, Susan Y Chu, Melinda Wharton.   

Abstract

BACKGROUND: Serologic data on diseases that are preventable by vaccine are useful to evaluate the success of immunization programs and to identify susceptible subgroups.
OBJECTIVE: To provide national estimates of immunity to diphtheria and tetanus by measurement of serum antibody levels.
DESIGN: Examination of data from the Third National Health and Nutrition Examination Survey, a representative cross-sectional sample of the U.S. population.
SETTING: 89 randomly selected locations throughout the United States. PARTICIPANTS: 18 045 persons 6 years of age or older who were examined from 1988 to 1994. MEASUREMENTS: Serum samples obtained at a single time point were tested for diphtheria and tetanus antitoxin.
RESULTS: Overall, 60.5% of Americans 6 years of age or older had fully protective levels of diphtheria antibody (> or =0.10 IU/mL) and 72.3% had protective levels of tetanus antibody (> 0.15 IU/mL). Ninety-one percent of Americans 6 to 11 years of age had protective levels of both diphtheria and tetanus antibody; this proportion decreased to approximately 30% among persons 70 years of age (29.5% for diphtheria and 31.0% for tetanus). Adult Mexican-Americans were slightly less likely to have protective levels of antibody to both toxins. Only 47% of persons 20 years of age or older had levels that were protective against both diseases, and only 63% of adults who were protected against tetanus were also protected against diphtheria.
CONCLUSIONS: A substantial proportion of adults in the United States do not have antibody levels that are protective against diphtheria and tetanus. In addition, although the recommended vaccine is a combination of tetanus and diphtheria, only 63% of adults with protective antibody to tetanus also had protective antibody to diphtheria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992301     DOI: 10.7326/0003-4819-136-9-200205070-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  22 in total

1.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

2.  Determination of tetanus antibodies by a double-antigen enzyme-linked immunosorbent assay in individuals of various age groups.

Authors:  K Caglar; R Karakus; C Aybay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

3.  The seroepidemiology of tetanus in Catalonia, Spain.

Authors:  A Domínguez; P Plans; J Costa; J Espuñes; N Cardeñosa; L Salleras; A Plasència
Journal:  Med Microbiol Immunol       Date:  2007-01-23       Impact factor: 3.402

4.  Routine adult immunization in Canada: recommendations and performance.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis       Date:  2002-07

5.  Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.

Authors:  Debraj GuhaThakurta; Nadeem A Sheikh; Li-Qun Fan; Harini Kandadi; T Craig Meagher; Simon J Hall; Philip W Kantoff; Celestia S Higano; Eric J Small; Thomas A Gardner; Kate Bailey; Tuyen Vu; Todd DeVries; James B Whitmore; Mark W Frohlich; James B Trager; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

6.  Comparison of five commercial anti-tetanus toxoid immunoglobulin G enzyme-linked immunosorbent assays.

Authors:  A L Perry; A J Hayes; H A Cox; F Alcock; A R Parker
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

Review 7.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

8.  Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis.

Authors:  Erika Hammarlund; Archana Thomas; Elizabeth A Poore; Ian J Amanna; Abby E Rynko; Motomi Mori; Zunqiu Chen; Mark K Slifka
Journal:  Clin Infect Dis       Date:  2016-03-21       Impact factor: 9.079

9.  Improving tetanus prophylaxis in the emergency department: a prospective, double-blind cost-effectiveness study.

Authors:  Muriel Stubbe; Luc J M Mortelmans; Didier Desruelles; Rohnny Swinnen; Marc Vranckx; Edmond Brasseur; Philippe E Lheureux
Journal:  Emerg Med J       Date:  2007-09       Impact factor: 2.740

10.  Evaluation for tetanus antibodies in Korean-Americans living in the New York area: a pilot study.

Authors:  Kumar Alagappan; Richard Park; Sassan Naderi; Robert Silverman
Journal:  J Immigr Minor Health       Date:  2008-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.